Risk factors for systemssic reactions to allergen immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 6, 2011, Pages 579-585

  Iglesias Cadarso, Alfredo ^a   Hernández Weigand, Pilar ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

adverse effects; allergen and sublingual immunotherapy; risk factors; subcutaneous immunotherapy; systemic reactions

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; OMALIZUMAB;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ASTHMA; DATA BASE; DRUG WITHDRAWAL; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; INTERMETHOD COMPARISON; MEDICAL ERROR; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMIC DISEASE; AGE; ANIMAL; CLINICAL TRIAL (TOPIC); CROSS REACTION; DESENSITIZATION; IMMUNOLOGY; MEDICATION ERROR; SEX DIFFERENCE;

AGE FACTORS; ANIMALS; CLINICAL TRIALS AS TOPIC; CROSS REACTIONS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; MEDICATION ERRORS; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; SEX FACTORS;

EID: 80255135645     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32834c229e     Document Type: Review

References (72)

1. Calderon MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30-38.
2. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66:740-752.
3. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126:466-476.
4. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1-S55.
5. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-562.
6. Guidelines to minimize the risk from systemic reactions caused by immunotherapy with allergenic extracts. AAAI Board of Directors. American Academy of Allergy and Immunology. J Allergy Clin Immunol 1994; 93:811-812.
7. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169-175.
8. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multicentric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004; 34:527-531.
9. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-677.
10. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993; 92:6-15.
11. Position paper: immunotherapy with hymenoptera venoms, (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993; 48:36-46.
12. Position paper: immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993; 48:7-35.
13. Position paper on allergen immunotherapy. Report of a BSACI working party. January-October 1992. Clin Exp Allergy 1993; 23(Suppl. 3):1-44.
14. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61 (Suppl. 82):1-20.
15. Zuberbier T, Bachert C, Bousquet PJ, et al. GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010; 65:1525-1530.
16. Windom HH, Lockey RF. An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008; 8:571-576.
17. Akkoc T, Akdis M, Akdis CA. Update in the mechanisms of allergen-specific immunotherapy. Allergy Asthma Immunol Res 2011; 3:11-20.
18. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009; 103:451-459.
19. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011; 127:64-71.
20. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-138.
21. Iglesias-Cadarso A, Hernandez-Weigand P, Reano M, et al. Risk factors for systemic reactions to allergen-specific subcutaneous immunotherapy. J Investig Allergol Clin Immunol 2010; 20:621-622.
22. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30:1423-1429.
23. Mosbech H, Muller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:1005-1010.
24. Nettis E, Giordano D, Pannofino A, et al. Safety of inhalant allergen immunotherapy with mass units-standardized extracts. Clin Exp Allergy 2002; 32:1745-1749.
25. Tabar AI, Garcia BE, Rodriguez A, et al. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48:450-453.
26. Iglesias-Cadarso A, Hernandez-Weigand P, Reano M, et al. A prospective safety study of allergen immunotherapy in daily clinical practice. Allergol Immunopathol 2004; 32:278-283.
27. Iglesias-Cadarso A. Re: a prospective safety study of allergen immunotherapy in daily clinical practice. Allergol Immunopathol 2007; 35:76.
28. Tabar AI, Lizaso MT, Garcia BE, et al. Tolerance of immunotherapy with a standardized extract of Alternaria tenuis in patients with rhinitis and bronchial asthma. J Investig Allergol Clin Immunol 2000; 10:327-333.
29. Rank MA, Oslie CL, Krogman JL, et al. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 2008; 29:400-405.
30. Specific allergen immunotherapy for asthma. A position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Med J Aust 1997; 167:540-544.
31. Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71:557-562.
32. Justicia JL, Barasona MJ, Serrano P, et al. Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol 2007; 17:386-392.
33. Da Veiga SP, Liu X, Caruso K, et al. Systemic reactions associated with subcutaneous allergen immunotherapy: timing and risk assessment. Ann Allergy Asthma Immunol 2011; 106:533-537.
34. Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol 2011; 127:8-15.
35. Gastaminza G, Algorta J, Audicana M, et al. Systemic reactions to immunotherapy: influence of composition and manufacturer. Clin Exp Allergy 2003; 33:470-474.
36. Winther L, Arnved J, Malling HJ, et al. Side-effects of allergen-specific immunotherapy: a prospective multicentre study. Clin Exp Allergy 2006; 36:254-260.
37. Businco L, Zannino L, Cantani A, et al. Systemic reactions to specific immunotherapy in children with respiratory allergy: a prospective study. Pediatr Allergy Immunol 1995; 6:44-47.
38. Tabar AI, Lizaso MT, Garcia BE, et al. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Pediatr Allergy Immunol 2008; 19:67-75.
39. Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775-780.
40. Till SJ, Durham SR. Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol 2008; 21:59-70.
41. Pfaar O, Klimek L, Sager A, Brautigam M. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma. Am J Rhinol Allergy 2010; 24:220-225.
42. Dubuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011; 32:239-247.
43. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper. Allergy 2009; 64 (Suppl. 91): 1-59.
44. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010; 40:922-932.
45. Didier A,Malling HJ, Worm M, et al.Optimal dose, efficacy, and safety of oncedaily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-1345.
46. Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011; 127: 974-981.
47. Rodriguez-Perez N, Ambriz-Moreno MJ, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008; 101:304-310.
48. De Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009; 64:963-964.
49. Krishna MT, Huissoon AP. Clinical immunology review series: an approach to desensitization. Clin Exp Immunol 2011; 163:131-146.
50. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63:374.
51. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists experiences and recommendations for prevention. J Allergy Clin Immunol 2004; 113:1117-1121.
52. Bernstein DI, Epstein T. Systemic reactions to subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am 2011; 31:241-249.
53. Pfaar O, Leitzbach S, Hormann K, Klimek L. Cluster protocols in SCIT: enough evidence for practical use? Curr Opin Allergy Clin Immunol 2010; 10:188-193.
54. Brehler R, Klimek L, Pfaar O, et al. Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. Allergy Asthma Proc 2010; 31:e31-e38.
55. Fernandez-Tavora L, Moreno C, Martin S, Rico P. The optimal immunotherapy cluster schedule in clinical practice. J Investig Allergol Clin Immunol 2003; 13:193-201.
56. Gorska L, Chelminska M, Kuziemski K, et al. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol 2008; 147:241-245.
57. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383-389.
58. Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19:225-229.
59. Mosges R, Graute V, Christ H, et al. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. Pediatr Allergy Immunol 2010; 21:1135-1138.
60. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing. J Allergy Clin Immunol 2004; 113:1129-1136.
61. Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96:600-605.
62. Nichani JR, de Carpentier J. Safety of sublingual grass pollen immunotherapy after anaphylaxis. J Laryngol Otol 2009; 123:683-684.
63. Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol 2009; 124:378-379.
64. Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99:82-86.
65. Calabria CW, Stolfi A, Tankersley MS. The REPEAT study: recognizing and evaluating periodic local reactions in allergen immunotherapy and associated systemic reactions. Ann Allergy Asthma Immunol 2011; 106:49-53.
66. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004; 92:225-227.
67. Bousquet J, Schunemann HJ, Bousquet PJ, et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIAGA2LEN statement. Allergy 2011; 66:765-774.
68. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-324.
69. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86):8-160.
70. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010; 125:569-574.
71. Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010; 104:530-535.
72. Madsen F, Frolund L, Christensen M, et al. Quality assurance of allergenspecific immunotherapy during a national outbreak of anaphylaxis: results of a continuous sentinel event surveillance system. J Investig Allergol Clin Immunol 2009; 19:253-259.